

Enzo Lalli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2674540/publications.pdf>

Version: 2024-02-01

160
papers

8,155
citations

53660

45
h-index

51492

86
g-index

171
all docs

171
docs citations

171
times ranked

6584
citing authors

#	ARTICLE	IF	CITATIONS
1	How good are the current models of adrenocortical carcinoma for novel drug discovery?. Expert Opinion on Drug Discovery, 2022, 17, 211-213.	2.5	2
2	Environmental Contaminants Modulate Breast Cancer Development and Outcome in TP53 p.R337H Carriers and Noncarriers. Cancers, 2022, 14, 3014.	1.7	1
3	Targeting the cytoskeleton against metastatic dissemination. Cancer and Metastasis Reviews, 2021, 40, 89-140.	2.7	34
4	The Common Germline <i>TP53-R337H</i> Mutation Is Hypomorphic and Confers Incomplete Penetrance and Late Tumor Onset in a Mouse Model. Cancer Research, 2021, 81, 2442-2456.	0.4	9
5	“You cannot expect miracles to happen overnight”: patience pays off when you wish to establish a new adrenocortical carcinoma cell line. European Journal of Endocrinology, 2021, 185, C9-C11.	1.9	2
6	Integrative genomic analysis reveals a conserved role for prolactin signalling in the regulation of adrenal function. Clinical and Translational Medicine, 2021, 11, e630.	1.7	4
7	Mitotane treatment in adrenocortical carcinoma: mechanisms of action and predictive markers of response to therapy. Minerva Endocrinology, 2021, , .	0.6	2
8	Editorial “Chaperones in endocrinology. Molecular and Cellular Endocrinology, 2020, 514, 110943.	1.6	0
9	Astemizole Sensitizes Adrenocortical Carcinoma Cells to Doxorubicin by Inhibiting Patched Drug Efflux Activity. Biomedicines, 2020, 8, 251.	1.4	7
10	A common polymorphism in the retinoic acid pathway modifies adrenocortical carcinoma age-dependent incidence. British Journal of Cancer, 2020, 122, 1231-1241.	2.9	8
11	Cancer-testis Antigen FATE1 Expression in Adrenocortical Tumors Is Associated with A Pervasive Autoimmune Response and Is A Marker of Malignancy in Adult, but Not Children, ACC. Cancers, 2020, 12, 689.	1.7	14
12	XAF1 as a modifier of p53 function and cancer susceptibility. Science Advances, 2020, 6, eaba3231.	4.7	37
13	Germline Variants in Phosphodiesterase Genes and Genetic Predisposition to Pediatric Adrenocortical Tumors. Cancers, 2020, 12, 506.	1.7	17
14	From adrenarche to aging of adrenal zona reticularis: precocious female adrenopause onset. Endocrine Connections, 2020, 9, 1212-1220.	0.8	4
15	Reduction of Fmr1 mRNA Levels Rescues Pathological Features in Cortical Neurons in a Model of FXTAS. Molecular Therapy - Nucleic Acids, 2019, 18, 546-553.	2.3	11
16	The Prognostic Role of CD8+ T Lymphocytes in Childhood Adrenocortical Carcinomas Compared to Ki-67, PD-1, PD-L1, and the Weiss Score. Cancers, 2019, 11, 1730.	1.7	25
17	ER-mitochondria interactions: Both strength and weakness within cancer cells. Biochimica Et Biophysica Acta - Molecular Cell Research, 2019, 1866, 650-662.	1.9	65
18	Spatial trends in congenital malformations and stream water chemistry in Southern Brazil. Science of the Total Environment, 2019, 650, 1278-1291.	3.9	11

#	ARTICLE	IF	CITATIONS
19	Fascin-1 Is a Novel Prognostic Biomarker Associated With Tumor Invasiveness in Adrenocortical Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 1712-1724.	1.8	28
20	The GRP78/BiP inhibitor HA15 synergizes with mitotane action against adrenocortical carcinoma cells through convergent activation of ER stress pathways. <i>Molecular and Cellular Endocrinology</i> , 2018, 474, 57-64.	1.6	33
21	Targeting the multidrug transporter Patched potentiates chemotherapy efficiency on adrenocortical carcinoma <i>in vitro</i> and <i>in vivo</i> . <i>International Journal of Cancer</i> , 2018, 143, 199-211.	2.3	21
22	The next step: mechanisms driving adrenocortical carcinoma metastasis. <i>Endocrine-Related Cancer</i> , 2018, 25, R31-R48.	1.6	13
23	Dosage-dependent regulation of <i>VAV2</i> expression by steroidogenic factor-1 drives adrenocortical carcinoma cell invasion. <i>Science Signaling</i> , 2017, 10, .	1.6	35
24	Modeling Fragile X syndrome in neurogenesis: An unexpected phenotype and a novel tool for future therapies. <i>Neurogenesis (Austin, Tex)</i> , 2017, 4, e1270384.	1.5	16
25	Small non-coding RNAs in endocrinology. <i>Molecular and Cellular Endocrinology</i> , 2017, 456, 1.	1.6	0
26	Assessment of VAV2 Expression Refines Prognostic Prediction in Adrenocortical Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 3491-3498.	1.8	33
27	The ER-mitochondria couple: In life and death from steroidogenesis to tumorigenesis. <i>Molecular and Cellular Endocrinology</i> , 2017, 441, 176-184.	1.6	17
28	Establishment of a mouse xenograft model of metastatic adrenocortical carcinoma. <i>Oncotarget</i> , 2017, 8, 51050-51057.	0.8	9
29	VAV2: a novel prognostic marker and a druggable target for adrenocortical carcinoma. <i>Oncotarget</i> , 2017, 8, 88257-88258.	0.8	6
30	NR5A1 (nuclear receptor subfamily 5, group A, member 1). <i>Atlas of Genetics and Cytogenetics in Oncology and Haematology</i> , 2017, , .	0.1	0
31	Impact of ACTH Signaling on Transcriptional Regulation of Steroidogenic Genes. <i>Frontiers in Endocrinology</i> , 2016, 7, 24.	1.5	68
32	<i>FATE</i> 1 antagonizes calcium- and drug-induced apoptosis by uncoupling <i>ER</i> and mitochondria. <i>EMBO Reports</i> , 2016, 17, 1264-1280.	2.0	102
33	ER-mitochondria contacts find their FATE. <i>Cell Cycle</i> , 2016, 15, 3159-3160.	1.3	2
34	[OP.3A.02] RETINOIC ACID RECEPTOR SIGNALING CONTRIBUTES TO ADRENAL CORTEX MORPHOLOGY AND FUNCTIONAL ZONATION. <i>Journal of Hypertension</i> , 2016, 34, e26.	0.3	0
35	5th International ACC Symposium: An Outlook to Current and Future Research on the Biology of Adrenocortical Carcinoma: Diagnostic and Therapeutic Applications. <i>Hormones and Cancer</i> , 2016, 7, 44-48.	4.9	3
36	Local Control of Aldosterone Production and Primary Aldosteronism. <i>Trends in Endocrinology and Metabolism</i> , 2016, 27, 123-131.	3.1	29

#	ARTICLE	IF	CITATIONS
37	Special issue on animal models in endocrine neoplasia. <i>Molecular and Cellular Endocrinology</i> , 2016, 421, 1.	1.6	0
38	CO-34: Retinoic acid receptor signaling contributes to adrenal morphology and functional zonation. <i>Annales De Cardiologie Et D'Angeiologie</i> , 2015, 64, S16.	0.3	0
39	DAX-1 Expression in Pediatric Rhabdomyosarcomas: Another Immunohistochemical Marker Useful in the Diagnosis of Translocation Positive Alveolar Rhabdomyosarcoma. <i>PLoS ONE</i> , 2015, 10, e0133019.	1.1	0
40	Natural paniceins from mediterranean sponge inhibit the multidrug resistance activity of Patched and increase chemotherapy efficiency on melanoma cells. <i>Oncotarget</i> , 2015, 6, 22282-22297.	0.8	24
41	Genome-Wide Paternal Uniparental Disomy as a Cause of Beckwith-Wiedemann Syndrome Associated with Recurrent Virilizing Adrenocortical Tumors. <i>Hormone and Metabolic Research</i> , 2015, 47, 497-503.	0.7	16
42	Mitotane Revisited: A New Target for an Old Drug. <i>Endocrinology</i> , 2015, 156, 3873-3875.	1.4	11
43	Pediatric Adrenocortical Tumors: What They Can Tell Us on Adrenal Development and Comparison with Adult Adrenal Tumors. <i>Frontiers in Endocrinology</i> , 2015, 6, 23.	1.5	44
44	How genomic studies have improved our understanding of the mechanisms of transcriptional regulation by NR5A nuclear receptors. <i>Molecular and Cellular Endocrinology</i> , 2015, 408, 138-144.	1.6	10
45	Two-pore domain potassium channels in the adrenal cortex. <i>Pflugers Archiv European Journal of Physiology</i> , 2015, 467, 1027-1042.	1.3	29
46	Role of Orphan Nuclear Receptor DAX-1/NROB1 in Development, Physiology, and Disease. <i>Advances in Biology</i> , 2014, 2014, 1-19.	1.2	11
47	Methodological pitfalls in the study of DAX-1 function. <i>Cell Death and Disease</i> , 2014, 5, e977-e977.	2.7	0
48	Vanin-1 Inactivation Antagonizes the Development of Adrenocortical Neoplasia in Sf-1 Transgenic Mice. <i>Endocrinology</i> , 2014, 155, 2349-2354.	1.4	18
49	Diagnostic and prognostic role of steroidogenic factor 1 in adrenocortical carcinoma: a validation study focusing on clinical and pathologic correlates. <i>Human Pathology</i> , 2013, 44, 822-828.	1.1	76
50	Lack of long-lasting effects of mitotane adjuvant therapy in a mouse xenograft model of adrenocortical carcinoma. <i>Molecular and Cellular Endocrinology</i> , 2013, 381, 66-69.	1.6	13
51	Beyond steroidogenesis: Novel target genes for SF-1 discovered by genomics. <i>Molecular and Cellular Endocrinology</i> , 2013, 371, 154-159.	1.6	30
52	Impact of Neonatal Screening and Surveillance for the TP53 R337H Mutation on Early Detection of Childhood Adrenocortical Tumors. <i>Journal of Clinical Oncology</i> , 2013, 31, 2619-2626.	0.8	156
53	Integrative analysis of SF-1 transcription factor dosage impact on genome-wide binding and gene expression regulation. <i>Nucleic Acids Research</i> , 2013, 41, 8896-8907.	6.5	40
54	Severe Hyperaldosteronism in Neonatal Task3 Potassium Channel Knockout Mice Is Associated With Activation of the Intraadrenal Renin-Angiotensin System. <i>Endocrinology</i> , 2013, 154, 2712-2722.	1.4	35

#	ARTICLE	IF	CITATIONS
55	Genomic Analysis of Sexual Dimorphism of Gene Expression in the Mouse Adrenal Gland. <i>Hormone and Metabolic Research</i> , 2013, 45, 870-873.	0.7	27
56	The Hedgehog Receptor Patched Functions in Multidrug Transport and Chemotherapy Resistance. <i>Molecular Cancer Research</i> , 2012, 10, 1496-1508.	1.5	33
57	Task3 Potassium Channel Gene Invalidation Causes Low Renin and Salt-Sensitive Arterial Hypertension. <i>Endocrinology</i> , 2012, 153, 4740-4748.	1.4	63
58	SNP Array Profiling of Childhood Adrenocortical Tumors Reveals Distinct Pathways of Tumorigenesis and Highlights Candidate Driver Genes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, E1284-E1293.	1.8	41
59	Dkk3 is a component of the genetic circuitry regulating aldosterone biosynthesis in the adrenal cortex. <i>Human Molecular Genetics</i> , 2012, 21, 4922-4929.	1.4	22
60	Efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 in a preclinical model of adrenocortical carcinoma. <i>Molecular and Cellular Endocrinology</i> , 2012, 364, 101-104.	1.6	29
61	Identity by Descent Mapping of Founder Mutations in Cancer Using High-Resolution Tumor SNP Data. <i>PLoS ONE</i> , 2012, 7, e35897.	1.1	8
62	Dysregulation of microRNAs in adrenocortical tumors. <i>Molecular and Cellular Endocrinology</i> , 2012, 351, 118-128.	1.6	34
63	Adrenal Cancer: Scientific Advances. <i>Molecular and Cellular Endocrinology</i> , 2012, 351, 1.	1.6	2
64	Genetics and genomics of childhood adrenocortical tumors. <i>Molecular and Cellular Endocrinology</i> , 2011, 336, 169-173.	1.6	17
65	The Wnt/beta-catenin pathway in adrenocortical development and cancer. <i>Molecular and Cellular Endocrinology</i> , 2011, 332, 32-37.	1.6	111
66	Increased Incidence of Choroid Plexus Carcinoma Due to the Germline TP53 R337H Mutation in Southern Brazil. <i>PLoS ONE</i> , 2011, 6, e18015.	1.1	63
67	Adrenal Cancer: Clinical Advances. <i>Hormones and Cancer</i> , 2011, 2, 323-323.	4.9	1
68	Aldosterone-Producing Adenoma Formation in the Adrenal Cortex Involves Expression of Stem/Progenitor Cell Markers. <i>Endocrinology</i> , 2011, 152, 4753-4763.	1.4	85
69	Gonadotropin-Dependent Precocious Puberty in a Patient with X-Linked Adrenal Hypoplasia Congenita Caused by a Novel DAX-1 Mutation. <i>Hormone Research in Paediatrics</i> , 2011, 75, 153-156.	0.8	22
70	Therapy of adrenocortical cancer: present and future. <i>American Journal of Cancer Research</i> , 2011, 1, 222-232.	1.4	12
71	Potent inhibitory effect of the cyclolignan picropodophyllin (PPP) on human adrenocortical carcinoma cells proliferation. <i>American Journal of Cancer Research</i> , 2011, 1, 356-361.	1.4	7
72	Heterozygous TP53stop146/R72P fibroblasts from a Li-Fraumeni syndrome patient with impaired response to DNA damage. <i>International Journal of Oncology</i> , 2010, 36, 983-90.	1.4	6

#	ARTICLE	IF	CITATIONS
73	Regulation of Insulin-like Growth Factorâ€™Mammalian Target of Rapamycin Signaling by MicroRNA in Childhood Adrenocortical Tumors. <i>Cancer Research</i> , 2010, 70, 4666-4675.	0.4	191
74	Adrenocortical development and cancer: focus on SF-1. <i>Journal of Molecular Endocrinology</i> , 2010, 44, 301-307.	1.1	46
75	Targeting DAX-1 in embryonic stem cells and cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2010, 14, 169-177.	1.5	25
76	Adrenal Cortex Remodeling and Functional Zona Glomerulosa Hyperplasia in Primary Aldosteronism. <i>Hypertension</i> , 2010, 56, 885-892.	1.3	128
77	Identification and Characterization of Steroidogenic Factor-1 Inverse Agonists. <i>Methods in Enzymology</i> , 2010, 485, 3-23.	0.4	7
78	Adrenal cortex ontogenesis. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2010, 24, 853-864.	2.2	9
79	Inhibition of Adrenocortical Carcinoma Cell Proliferation by Steroidogenic Factor-1 Inverse Agonists. <i>Endocrine Reviews</i> , 2009, 30, 290-290.	8.9	0
80	FRAXE-associated mental retardation protein (FMR2) is an RNA-binding protein with high affinity for G-quartet RNA forming structure. <i>Nucleic Acids Research</i> , 2009, 37, 1269-1279.	6.5	67
81	Inhibition of Adrenocortical Carcinoma Cell Proliferation by Steroidogenic Factor-1 Inverse Agonists. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 2178-2183.	1.8	77
82	Differential Effects of High and Low Steroidogenic Factor-1 Expression on CYP11B2 Expression and Aldosterone Production in Adrenocortical Cells. <i>Endocrinology</i> , 2009, 150, 1303-1309.	1.4	46
83	E3 Ubiquitin Ligase RNF31 Cooperates with DAX-1 in Transcriptional Repression of Steroidogenesis. <i>Molecular and Cellular Biology</i> , 2009, 29, 2230-2242.	1.1	43
84	Dax-1 Knockdown in Mouse Embryonic Stem Cells Induces Loss of Pluripotency and Multilineage Differentiation. <i>Stem Cells</i> , 2009, 27, 1529-1537.	1.4	70
85	A matter of dosage: SF-1 in adrenocortical development and cancer. <i>Annales D'Endocrinologie</i> , 2009, 70, 148-152.	0.6	8
86	Inhibition of Adrenocortical Carcinoma Cell Proliferation by Steroidogenic Factor-1 Inverse Agonists. <i>Molecular Endocrinology</i> , 2009, 23, 736-736.	3.7	0
87	DAX1, a direct target of EWS/FLI1 oncoprotein, is a principal regulator of cell-cycle progression in Ewing's tumor cells. <i>Oncogene</i> , 2008, 27, 6034-6043.	2.6	100
88	Invalidation of TASK1 potassium channels disrupts adrenal gland zonation and mineralocorticoid homeostasis. <i>EMBO Journal</i> , 2008, 27, 179-187.	3.5	168
89	High frequency of loss of heterozygosity at 11p15 and IGF2 overexpression are not related to clinical outcome in childhood adrenocortical tumors positive for the R337H TP53 mutation. <i>Cancer Genetics and Cytogenetics</i> , 2008, 186, 19-24.	1.0	27
90	DAX1 is a direct target of EWS/FLI1 oncoprotein and a principal regulator of cell cycle progression in Ewing tumor cells. <i>European Journal of Cancer, Supplement</i> , 2008, 6, 34.	2.2	0

#	ARTICLE	IF	CITATIONS
91	The T cell factor/ β -Catenin Antagonist PKF115584 Inhibits Proliferation of Adrenocortical Carcinoma Cells. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 3222-3225.	1.8	88
92	Gene Expression Profiling of Childhood Adrenocortical Tumors. <i>Cancer Research</i> , 2007, 67, 600-608.	0.4	146
93	Increased Steroidogenic Factor-1 Dosage Triggers Adrenocortical Cell Proliferation and Cancer. <i>Molecular Endocrinology</i> , 2007, 21, 2968-2987.	3.7	194
94	Regulation of Human MC2-R Gene Expression by CREB, CREM, and ICER in the Adrenocortical Cell Line Y1. <i>Hormone and Metabolic Research</i> , 2007, 39, 560-566.	0.7	8
95	Nephroblastoma Overexpressed/Cysteine-Rich Protein 61/Connective Tissue Growth Factor/Nephroblastoma Overexpressed Gene-3 (NOV/CCN3), a Selective Adrenocortical Cell Proapoptotic Factor, Is Down-Regulated in Childhood Adrenocortical Tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 3253-3260.	1.8	52
96	Transcriptional Regulation of the Glucose-6-phosphatase Gene by cAMP/Vasoactive Intestinal Peptide in the Intestine. <i>Journal of Biological Chemistry</i> , 2006, 281, 31268-31278.	1.6	46
97	SF-1 overexpression in childhood adrenocortical tumours. <i>European Journal of Cancer</i> , 2006, 42, 1040-1043.	1.3	90
98	Partial defects in transcriptional activity of two novel DAX-1 mutations in childhood-onset adrenal hypoplasia congenita. <i>Clinical Endocrinology</i> , 2006, 65, 681-686.	1.2	11
99	The orphan nuclear receptor DAX1 is up-regulated by the EWS/FLI1 oncoprotein and is highly expressed in Ewing tumors. <i>International Journal of Cancer</i> , 2006, 118, 1381-1389.	2.3	75
100	Fragile X related protein 1 isoforms differentially modulate the affinity of fragile X mental retardation protein for G-quartet RNA structure. <i>Nucleic Acids Research</i> , 2006, 35, 299-306.	6.5	49
101	Specific Immunoassays for Placental Alkaline Phosphatase As a Tumor Marker. <i>Journal of Biomedicine and Biotechnology</i> , 2006, 2006, 1-8.	3.0	8
102	Transcriptional Regulation of the Glucose-6-phosphatase Gene by cAMP/Vasoactive Intestinal Peptide in the Intestine. <i>Journal of Biological Chemistry</i> , 2006, 281, 31268-31278.	1.6	13
103	Heat Shock Affects Trafficking of DAX-1 by Inducing Its Rapid and Reversible Cytoplasmic Localization. <i>Endocrine</i> , 2005, 28, 137-144.	2.2	6
104	Regulation of adrenocortical cardiogenic steroid production by dopamine and PKA signaling. <i>Frontiers in Bioscience - Landmark</i> , 2005, 10, 2489.	3.0	8
105	Extracellular Matrix and Hormones Modulate DAX-1 Localization in the Human Fetal Adrenal Gland. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 5426-5431.	1.8	22
106	Clinical and molecular evidence for DAX-1 inhibition of steroidogenic factor-1-dependent ACTH receptor gene expression. <i>European Journal of Endocrinology</i> , 2005, 152, 769-776.	1.9	11
107	Combinations of genetic changes in the human cAMP-responsive element modulator gene: a clue towards understanding some forms of male infertility?. <i>Molecular Human Reproduction</i> , 2005, 11, 567-574.	1.3	20
108	Amplification of the Steroidogenic Factor 1 Gene in Childhood Adrenocortical Tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 615-619.	1.8	120

#	ARTICLE	IF	CITATIONS
109	Regulation of ACTH-R gene expression by CREB, CREMt and ICER in the adrenocortical cell line Y1. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2005, 113, .	0.6	0
110	NUFIP1 (nuclear FMRP interacting protein 1) is a nucleocytoplasmic shuttling protein associated with active synaptoneuroosomes. <i>Experimental Cell Research</i> , 2003, 289, 95-107.	1.2	53
111	DAX-1, an Unusual Orphan Receptor at the Crossroads of Steroidogenic Function and Sexual Differentiation. <i>Molecular Endocrinology</i> , 2003, 17, 1445-1453.	3.7	149
112	Structure-function analysis reveals the molecular determinants of the impaired biological function of DAX-1 mutants in AHC patients. <i>Human Molecular Genetics</i> , 2003, 12, 1063-1072.	1.4	44
113	Transcriptional regulation of the mouse steroidogenic acute regulatory protein gene by the cAMP response-element binding protein and steroidogenic factor 1. <i>Journal of Molecular Endocrinology</i> , 2003, 30, 381-397.	1.1	111
114	Sexy splicing: regulatory interplays governing sex determination from Drosophila to mammals. <i>Journal of Cell Science</i> , 2003, 116, 441-445.	1.2	36
115	Regulation of Niemann-Pick C1 Gene Expression by the 3'5'-Cyclic Adenosine Monophosphate Pathway in Steroidogenic Cells. <i>Molecular Endocrinology</i> , 2003, 17, 704-715.	3.7	31
116	Regulation of Steroidogenesis and the Steroidogenic Acute Regulatory Protein by a Member of the cAMP Response-Element Binding Protein Family. <i>Molecular Endocrinology</i> , 2002, 16, 184-199.	3.7	200
117	X-linked adrenal hypoplasia congenita is caused by abnormal nuclear localization of the DAX-1 protein. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 8225-8230.	3.3	46
118	A direct role of SRY and SOX proteins in pre-mRNA splicing. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 1146-1151.	3.3	106
119	SF-1 (Steroidogenic Factor-1), C/EBP β (CCAAT/Enhancer Binding Protein), and Ubiquitous Transcription Factors NF1 (Nuclear Factor 1) and Sp1 (Selective Promoter Factor 1) Are Required for Regulation of the Mouse Aldose Reductase-Like Gene (AKR1B7) Expression in Adrenocortical Cells. <i>Molecular Endocrinology</i> , 2001, 15, 93-111.	3.7	40
120	Heat Shock Interferes with Steroidogenesis by Reducing Transcription of the Steroidogenic Acute Regulatory Protein Gene. <i>Molecular Endocrinology</i> , 2001, 15, 1255-1263.	3.7	31
121	SF-1 (Steroidogenic Factor-1), C/EBP β (CCAAT/Enhancer Binding Protein), and Ubiquitous Transcription Factors NF1 (Nuclear Factor 1) and Sp1 (Selective Promoter Factor 1) Are Required for Regulation of the Mouse Aldose Reductase-Like Gene (AKR1B7) Expression in Adrenocortical Cells. <i>Molecular Endocrinology</i> , 2001, 15, 93-111.	3.7	24
122	Orphan Receptor DAX-1 Is a Shuttling RNA Binding Protein Associated with Polyribosomes via mRNA. <i>Molecular and Cellular Biology</i> , 2000, 20, 4910-4921.	1.1	109
123	Mammalian Bufadienolide Is Synthesized From Cholesterol in the Adrenal Cortex by a Pathway That Is Independent of Cholesterol Side-Chain Cleavage. <i>Hypertension</i> , 2000, 36, 442-448.	1.3	67
124	DAX-1 and the adrenal cortex. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 1999, 6, 185.	0.6	12
125	DAX-1 Expression in Human Adrenocortical Neoplasms: Implications for Steroidogenesis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998, 83, 2597-2600.	1.8	42
126	DAX-1 Blocks Steroid Production at Multiple Levels ¹ . <i>Endocrinology</i> , 1998, 139, 4237-4243.	1.4	167

#	ARTICLE	IF	CITATIONS
127	A Transcriptional Silencing Domain in DAX-1 Whose Mutation Causes Adrenal Hypoplasia Congenita. <i>Molecular Endocrinology</i> , 1997, 11, 1950-1960.	3.7	166
128	DNA binding and transcriptional repression by DAX-1 blocks steroidogenesis. <i>Nature</i> , 1997, 390, 311-315.	13.7	401
129	6 Coupling transcription to signaling pathways. <i>Advances in Second Messenger and Phosphoprotein Research</i> , 1997, , 63-74.	4.5	4
130	Coupling Signal Transduction to Transcription: The Nuclear Response to cAMP. , 1997, , 265-279.		0
131	The nuclear response to cAMP: role of transcription factor CREM. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 1996, 351, 201-209.	1.8	28
132	CREM: a master-switch in the transcriptional response to cAMP. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 1996, 351, 561-567.	1.8	37
133	DNA ploidy analysis of squamous cell carcinomas of the oral and maxillofacial region. <i>Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics</i> , 1996, 82, 308-314.	1.6	9
134	Block of T lymphocyte differentiation by activation of the cAMP-dependent signal transduction pathway.. <i>EMBO Journal</i> , 1996, 15, 528-537.	3.5	52
135	Steroidogenic factor 1 and Dax-1 colocalize in multiple cell lineages: potential links in endocrine development.. <i>Molecular Endocrinology</i> , 1996, 10, 1261-1272.	3.7	248
136	Hormonal and developmental regulation of DAX-1 expression in Sertoli cells.. <i>Molecular Endocrinology</i> , 1996, 10, 1561-1569.	3.7	101
137	Steroidogenic factor 1 and Dax-1 colocalize in multiple cell lineages: potential links in endocrine development. <i>Molecular Endocrinology</i> , 1996, 10, 1261-1272.	3.7	185
138	Hormonal and developmental regulation of DAX-1 expression in Sertoli cells. <i>Molecular Endocrinology</i> , 1996, 10, 1561-1569.	3.7	76
139	CREM. , 1996, , 143-160.		0
140	Thyroid-stimulating hormone (TSH)-directed induction of the CREM gene in the thyroid gland participates in the long-term desensitization of the TSH receptor.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1995, 92, 9633-9637.	3.3	95
141	CREM, a master-switch in the nuclear response to cAMP signaling. , 1995, , 1-38.		1
142	Complexity and versatility of the transcriptional response to cAMP. <i>Reviews of Physiology, Biochemistry and Pharmacology</i> , 1994, 124, 1-28.	0.9	42
143	Quality control for evaluation of the S-phase fraction by flow cytometry: A multicentric study. <i>Cytometry</i> , 1994, 18, 11-16.	1.8	36
144	An unusual member of the nuclear hormone receptor superfamily responsible for X-linked adrenal hypoplasia congenita. <i>Nature</i> , 1994, 372, 635-641.	13.7	796

#	ARTICLE	IF	CITATIONS
145	Decreased adhesion to endothelial cells and matrix proteins of H-2Kb gene transfected tumour cells. British Journal of Cancer, 1993, 68, 862-867.	2.9	10
146	Inducibility and negative autoregulation of CREM: An alternative promoter directs the expression of ICER, an early response repressor. Cell, 1993, 75, 875-886.	13.5	576
147	Nuclear response to cyclic AMP: central role of transcription factor CREM (cyclic-AMP-responsive-element modulator). Biochemical Society Transactions, 1993, 21, 912-917.	1.6	13
148	Increased serum concentrations of tumour necrosis factor in beta thalassaemia: effect of bone marrow transplantation.. Journal of Clinical Pathology, 1992, 45, 61-65.	1.0	12
149	Serum amyloid A protein concentration in bone marrow transplantation for beta thalassaemia.. Journal of Clinical Pathology, 1992, 45, 348-351.	1.0	6
150	Control of H-2 expression in transformed nonhaemopoietic cells by autocrine interferon. British Journal of Cancer, 1992, 66, 479-482.	2.9	3
151	Serum markers of immune activation and liver allograft rejection. Digestive Diseases and Sciences, 1992, 37, 1116-1120.	1.1	16
152	In situ hybridization in suspension and flow cytometry as a tool for the study of gene expression. Analytical Biochemistry, 1992, 207, 298-303.	1.1	33
153	Reduced adhesion to endothelial cells and reduced metastatic ability of H-2Kb transfectants. European Journal of Cancer & Clinical Oncology, 1991, 27, S31.	0.9	0
154	Integrins and other cell adhesion molecules of human rhabdomyosarcoma cells " Correlations with myogenic differentiation and with experimental metastatic ability. European Journal of Cancer & Clinical Oncology, 1991, 27, S34.	0.9	0
155	Commercial serum-free media: hybridoma growth and monoclonal antibody production. Journal of Immunological Methods, 1991, 145, 175-183.	0.6	17
156	Idiopathic pulmonary fibrosis: can cell mediated immunity markers predict clinical outcome?. Thorax, 1990, 45, 536-540.	2.7	18
157	DAX-1 Expression in Human Adrenocortical Neoplasms: Implications for Steroidogenesis. , 0, .		18
158	Role of steroidogenic factor-1 in the pathogenesis of adrenocortical tumours. Endocrine Abstracts, 0, , .	0.0	0
159	The role of p27 in pheochromocytoma development. Endocrine Abstracts, 0, , .	0.0	0
160	Contribution of retinoic acid receptor signalling to adrenal cortex morphology and functional zonation through modulation of WNT/[beta]-catenin pathway. Endocrine Abstracts, 0, , .	0.0	0